Zacks: Analysts Expect Jounce Therapeutics Inc (NASDAQ:JNCE) to Announce $2.34 EPS

Equities analysts expect Jounce Therapeutics Inc (NASDAQ:JNCE) to announce earnings of $2.34 per share for the current quarter, Zacks reports. Four analysts have made estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at $2.70 and the lowest estimate coming in at $1.83. Jounce Therapeutics reported earnings per share of ($0.23) in the same quarter last year, which would suggest a positive year-over-year growth rate of 1,117.4%. The business is expected to issue its next quarterly earnings report on Tuesday, November 12th.

On average, analysts expect that Jounce Therapeutics will report full-year earnings of $1.66 per share for the current year, with EPS estimates ranging from $1.12 to $2.28. For the next year, analysts anticipate that the firm will post earnings of ($2.87) per share, with EPS estimates ranging from ($3.90) to ($1.27). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.05. The company had revenue of $17.45 million during the quarter, compared to analysts’ expectations of $17.09 million. Jounce Therapeutics had a negative net margin of 46.07% and a negative return on equity of 29.64%.

Separately, JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Jounce Therapeutics in a research note on Sunday, August 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $10.00.

Shares of JNCE traded up $0.02 during mid-day trading on Friday, hitting $3.96. 178,500 shares of the company’s stock were exchanged, compared to its average volume of 327,194. The company has a market cap of $135.55 million, a PE ratio of -4.71 and a beta of 3.44. Jounce Therapeutics has a 52 week low of $2.66 and a 52 week high of $8.58. The company has a 50-day simple moving average of $4.43 and a 200 day simple moving average of $5.03. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.03 and a quick ratio of 2.03.

Several institutional investors and hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. grew its stake in shares of Jounce Therapeutics by 249.6% during the 2nd quarter. Meeder Asset Management Inc. now owns 5,034 shares of the company’s stock worth $25,000 after acquiring an additional 3,594 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Jounce Therapeutics by 3.0% in the 2nd quarter. Northern Trust Corp now owns 189,363 shares of the company’s stock valued at $937,000 after buying an additional 5,604 shares during the last quarter. Bailard Inc. boosted its holdings in shares of Jounce Therapeutics by 54.1% in the 2nd quarter. Bailard Inc. now owns 22,800 shares of the company’s stock valued at $113,000 after buying an additional 8,000 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Jounce Therapeutics by 37.4% in the 4th quarter. Bank of America Corp DE now owns 35,082 shares of the company’s stock valued at $118,000 after buying an additional 9,544 shares during the last quarter. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Jounce Therapeutics in the 2nd quarter valued at approximately $59,000. 73.54% of the stock is owned by institutional investors.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Featured Article: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.